<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7961321</article-id><article-id pub-id-type="publisher-id">5137</article-id><article-id pub-id-type="doi">10.1186/s13063-021-05137-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter</subject></subj-group></article-categories><title-group><article-title>COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wel&#x000e9;n</surname><given-names>Karin</given-names></name><address><email>karin.welen@gu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;verby</surname><given-names>Anna K</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ahlm</surname><given-names>Clas</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Freyhult</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Robinsson</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Henningsson</surname><given-names>Anna Jonsson</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Stranne</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bremell</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Angelin</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lindquist</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Buckland</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Carlsson</surname><given-names>Camilla Thellenberg</given-names></name><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Pauksens</surname><given-names>Karlis</given-names></name><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Bill-Axelsson</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Akre</surname><given-names>Olof</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Ryden</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Wagenius</surname><given-names>Magnus</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Bjartell</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Nilsson</surname><given-names>Anna C.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><name><surname>Styrke</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Repo</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Balkhed</surname><given-names>&#x000c5;se &#x000d6;stholm</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Niward</surname><given-names>Katarina</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Gissl&#x000e9;n</surname><given-names>Magnus</given-names></name><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Josefsson</surname><given-names>Andreas</given-names></name><address><email>Andreas.josefsson@umu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution>Department of Urology/Sahlgrenska Center for Cancer Research, </institution><institution>Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, </institution></institution-wrap>405 30 Gothenburg, Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Clinical Microbiology, Section of Virology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Molecular Infection Medicine Sweden, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Clinical Microbiology, Section of Infection and Immunology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution>Department of Medical Sciences, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff6"><label>6</label>Department of Urology, Region of J&#x000f6;nk&#x000f6;ping, J&#x000f6;nk&#x000f6;ping, Sweden </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.5640.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 2162 9922</institution-id><institution>Department of Biomedical and Clinical Sciences, </institution><institution>Link&#x000f6;ping University, </institution></institution-wrap>Link&#x000f6;ping, Sweden </aff><aff id="Aff8"><label>8</label>Department of Clinical Microbiology, Region J&#x000f6;nk&#x000f6;ping County, J&#x000f6;nk&#x000f6;ping, Sweden </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.8761.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9919 9582</institution-id><institution>Department of Infectious Diseases, </institution><institution>Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, </institution></institution-wrap>Gothenburg, Sweden </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Surgical and Perioperative Sciences, Urology &#x00026; Andrology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>901 87 Ume&#x000e5;, Sweden </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Wallenberg Center for Molecular Medicine, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="GRID">grid.12650.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 1034 3451</institution-id><institution>Department of Radiation Sciences, Oncology, </institution><institution>Ume&#x000e5; University, </institution></institution-wrap>Ume&#x000e5;, Sweden </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.412354.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2351 3333</institution-id><institution>Department of Infectious Diseases, </institution><institution>Uppsala University Hospital, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution>Department of Surgical Sciences, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.4714.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0626</institution-id><institution>Department of Molecular Medicine and Surgery, </institution><institution>Karolinska Institutet, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution>Division of Infection Medicine, Department of Clinical Sciences, </institution><institution>Lund University, </institution></institution-wrap>Lund, Sweden </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution>Division of Urological Cancers, Department of Translational Medicine, </institution><institution>Lund University, </institution></institution-wrap>Malm&#x000f6;, Sweden </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution>Department of Translational Medicine, Infectious Diseases Research Unit, </institution><institution>Lund University, </institution></institution-wrap>Malm&#x000f6;, Sweden </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="GRID">grid.1649.a</institution-id><institution-id institution-id-type="ISNI">000000009445082X</institution-id><institution>Department of Infectious Diseases, </institution><institution>Sahlgrenska University Hospital, </institution></institution-wrap>Region V&#x000e4;stra G&#x000f6;taland, Gothenburg, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>16</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>22</volume><elocation-id>209</elocation-id><history><date date-type="received"><day>15</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>18</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1">The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observation that the majority of patients in need of intensive care are male, and the connection between androgen receptor signalling and expression of TMPRSS2, an enzyme important for SARS-CoV-2 host cell internalization.</p></sec><sec><title>Trial design</title><p id="Par2">Hospitalised COVID-19 patients will be randomised (2:1) to enzalutamide plus standard of care vs. standard of care designed to identify superiority.</p></sec><sec><title>Participants</title><p id="Par3">Included participants, men or women above 50 years of age, must be hospitalised for PCR confirmed COVID-19 symptoms and not in need of immediate mechanical ventilation. Major exclusion criteria are breast-feeding or pregnant women, hormonal treatment for prostate or breast cancer, treatment with immunosuppressive drugs, current symptomatic unstable cardiovascular disease (see Additional file <xref rid="MOESM1" ref-type="media">1</xref> for further details). The trial is registered at Ume&#x000e5; University Hospital, Region V&#x000e4;sterbotten, Sweden and 8 hospitals are approved for inclusion in Sweden.</p></sec><sec><title>Intervention and comparator</title><p id="Par4">Patients randomised to the treatment arm will be treated orally with 160 mg (4x40 mg) enzalutamide (Xtandi&#x000ae;) daily, for five consecutive days. The study is not placebo controlled. The comparator is standard of care treatment for patients hospitalised with COVID-19.</p></sec><sec><title>Main outcomes</title><p id="Par5">The primary endpoints of the study are (time to) need of mechanical ventilation or discharge from hospital as assessed by a clinical 7-point ordinal scale (up to 30 days after inclusion).</p></sec><sec><title>Randomisation</title><p id="Par6">Randomisation was stratified by center and sex. Each strata was randomized separately with block size six with a 2:1 allocation ratio (enzalutamide + &#x0201c;standard of care&#x0201d;: &#x0201c;standard of care&#x0201d;). The randomisation list, with consecutive subject numbers, was generated by an independent statistician using the PROC PLAN procedure of SAS version 9.4 software (SAS Institute, Inc, Cary, North Carolina)</p></sec><sec><title>Blinding (masking)</title><p id="Par7">This is an open-label trial.</p></sec><sec><title>Numbers to be randomised (sample size)</title><p id="Par8">The trial is designed to have three phases. The first, an exploration phase of 45 participants (30 treatment and 15 control) will focus on safety and includes a more extensive laboratory assessment as well as more frequent safety evaluation. The second prolongation phase, includes the first 100 participants followed by an interim analysis to define the power of the study. The third phase is the continuation of the study up to maximum 600 participants included in total.</p></sec><sec><title>Trial Status</title><p id="Par9">The current protocol version is COVIDENZA v2.0 as of September 10, 2020. Recruitment started July 29, 2020 and is presently in safety pause after the first exploration phase. Recruitment is anticipated to be complete by 31 December 2021.</p></sec><sec><title>Trial registration</title><p id="Par10">Eudract number 2020-002027-10</p><p id="Par11">ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002027-10/SE">NCT04475601</ext-link>, registered June 8, 2020</p></sec><sec><title>Full protocol</title><p id="Par12">The full protocol is attached as an additional file, accessible from the Trials website (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13063-021-05137-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Randomised controlled trial</kwd><kwd>multicentre</kwd><kwd>protocol</kwd><kwd>enzalutamide</kwd><kwd>androgen signalling</kwd><kwd>TMPRSS2</kwd><kwd>antiandrogen</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>WCMM Fellow</award-id><principal-award-recipient><name><surname>Josefsson</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006044</institution-id><institution>Astellas Pharma Europe</institution></institution-wrap></funding-source><award-id>Unconditional grant</award-id><principal-award-recipient><name><surname>Josefsson</surname><given-names>Andreas</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Umea University</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec1"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13063_2021_5137_MOESM1_ESM.docx"><caption><p><bold>Additional file 1:.</bold> Full study protocol.</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Support, project management and facilities to conduct the study were provided by Clinical Research Center, Ume&#x000e5; University Hospital. Thanks to the clinical trial unit in Ume&#x000e5;: Marja-Liisa Lammi Tavelin, Lisette Marjavaara, Emma Wede, Kristina &#x000d6;jbrant, Ida Lundstr&#x000f6;m and Anna Ramnemark for excellent ongoing help with the startup and continued work with the trial, thanks also to the Centre for Clinical Cancer studies at Karolinska Institute for skillful help (Sanna Nystr&#x000f6;m and Susanne Wallberg). We also thank Fredrik Granstr&#x000f6;m at ITS (ICT Services and System Development at Ume&#x000e5; University) for helping us create the electronic Clinical Report Form, and also thanks to Sonja Huld&#x000e9;n, judge of appeal, for legal support.</p><p>Thanks also to all research personnel with all the work with starting up the trial at respective sites and for feedback to help us improve the trial: Frida Samuelsson, Jennie Bobeck, Mia Mickelsson, Helena Gissl&#x000e9;n, Jenny Holm Fernstr&#x000f6;m, Ann Carlstrand, Elisabeth Bengtsson, Kristina From, Sofia Sj&#x000f6;berg, Jennifer Amidi, Annika L&#x000f6;fgren, Suzy Lindberg, Malin Karlstr&#x000f6;m, Mathias Cort&#x000e9;s Rico, Malin Lindell, Beatrice Backman L&#x000f6;nn, Maria Casserdahl, Kerstin Almroth, Britt-Inger Dahlin, Ester Fridenstr&#x000f6;m, Malin Hellgren, Rebecka Sund&#x000e9;n , Ann-Charlotte Borgefeldt, Yvonne Pantzar, Cecilia Magnusson</p><p>We thank the Data Safety and Monitoring board for taking on the responsibility of this important and crucial work to externally review the ongoing trial: Associate Professor Martin Eklund, Professor Annika Bergquist, Associate Professor Jan Adolfsson, Professor Lars Hagberg, Professor Jan-Erik Damber, and Senior Medical Advisor Hel&#x000e9;n Seeman-Lodding</p><p>Thanks also to statistician Professor Marie Eriksson (Ume&#x000e5; Univerisity) for help with the randomization process.</p><p>We also acknowledge the work from the biobanks in the different regions: Biobank West, Biobank North, Uppsala Biobank, Biobank facility at Malm&#x000f6;, Sundsvall, Link&#x000f6;ping and J&#x000f6;nk&#x000f6;ping.</p><p>The authors are grateful for the unconditional support received from Astellas Pharma Europe&#x000ae;. The trial is also funded by the Knut and Alice Wallenberg foundation (Andreas Josefsson)</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AJ &#x02013; PI, concept and design of the study, including protocol writing and management. KW &#x02013; co-PI, concept and design of the study, including protocol writing and management. EF-Statistician. CA, MG, AB and AN- consultation for protocol concept, design and conduct. CTK &#x02013; consultation of design and safety evaluation. A&#x000d6;W&#x02013; preclinical studies for rationale of the trial, virology expertise. RB- trial management board. JStr, DB, JSty, JR, &#x000c5;&#x000d6;B, KN, DR, AJH, KP, AB-A, OA, CR, MW, MA and EL -Investigators at sites. All have participated in the review of this paper. The author(s) read and approved the final manuscript.</p><sec id="FPar1"><title>Authors&#x02019; information</title><p id="Par13">This is an academic trial and AJ and KW are independent researchers at Ume&#x000e5; and Gothenburg University.</p></sec></notes><notes notes-type="funding-information"><title>Funding</title><p>This investigator initiated trial is supported by an unconditional research grant from Astellas Pharma Ltd. Astellas Pharma had no role in the design of the study and has no role in data collection, nor analysis, nor interpretation of data, nor in writing any manuscript. Open Access funding provided by Umea University. Knut and Alice Wallenberg foundation (Andreas Josefsson).</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The trial board will have access to the final trial and no contractual agreements limit the access to the dataset.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par14">The trial with reference number 2020-02122 was approved by the Swedish Ethical Review Authority May 13, 2020. Due to special requirements to limit virus spread, local variations in the procedures for obtaining informed consent were allowed. However, all participants were informed and understood the consequences of the trial, before signing the informed consent form.</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par15">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par16">The authors declare that they have no competing interests.</p></notes></notes></back></article>